Navigation Links
Aegera Therapeutics collaboration with Human Genome Sciences leads to the initiation of a Phase 1 clinical trial with lead IAP inhibitor HGS1029 and receipt of first milestone payment
Date:6/10/2008

MONTREAL, June 10 /PRNewswire/ - Aegera Therapeutics Inc. is extremely pleased to announce the initiation of a Phase 1 clinical trial of the IAP ("Inhibitor of Apoptosis Protein") inhibitor, HGS1029 (formerly AEG40826), as a monotherapy in patients with advanced solid tumors. This small molecule IAP inhibitor was developed by Aegera and licensed to Human Genome Sciences, Inc. (Nasdaq: HGSI) for oncology development in December 2007. As part of this agreement, Aegera maintains full ownership of all rights to this class of molecules for the Japanese market and global rights for non-oncology indications.

"We are impressed with the research and development teams that HGS has applied to the advancement of this exciting collaborative oncology program. In a very short period of time, their clinical team has advanced this program to its first clinical trial and we are confident that their pro-active approach will lead to the rapid and successful development of this potent molecule across a broad range of cancer indications. In addition, our respective research teams are working very closely together to continue to build on Aegera's IAP expertise and to identify additional back-up and best-in-class compounds to follow the initial lead." commented Dr. Mike Berendt, Aegera President & CEO.

Aegera also announced today the receipt of its first milestone payment under this collaboration agreement. The payment, in the amount of US$5 million, was triggered by the FDA clearance of the Investigational New Drug (IND) application for HGS1029.

About Aegera Therapeutics Inc.

Aegera Therapeutics is a clinical stage biotechnology company focused on developing drugs that control apoptosis to address major unmet medical needs. In additi
'/>"/>

SOURCE AEGERA THERAPEUTICS INC.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Aegera Therapeutics welcomes two experienced executives to its board of directors
2. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
3. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
4. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Arana Therapeutics Ltd.
5. Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program
6. Loic Maurel Joins Exonhit Therapeutics to Become CEO
7. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
8. CV Therapeutics Announces Presentations at the American Diabetes Association 68th Scientific Sessions
9. Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 2008
10. Takedas Antibody Therapeutics Research Company, Takeda San Francisco, Inc. Appoints Mary Haak-Frendscho, Ph.D. as President and CSO
11. Bharatt Chowrira Joins Nektar Therapeutics as Chief Operating Officer and Head of PEGylation Business Unit

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)... Contec’s Sporicidin disinfectant solut...grade disinfectants against H1N1 and Influenza A.,...) November 24, 2009 -- Contec Inc, the leading man...that their Sporicidin disinfectants have been de... A viruses, including Pandemic 2009 H1N1 influenza...
(Date:11/23/2009)...ov.23/PRNewswire/-InimexPharmaceuticals,Inc.announ...sPresidentandCEO. ,, Abramsbringsmorethan25year...eisaco-inventorofthenuclearmedicineimagingagent,Ca...lcwherehewasManager,BiomedicalResearchWorldwide.In...CandwasPresidentandCEOfrom1996to2006.AnorMEDdiscov...
(Date:11/23/2009)...Calif.,Nov.23/PRNewswire/--PearlTherapeuticsInc.,a...ctsforthetreatmentofchronicrespiratorydiseases,tod...sBoardofDirectors.Mr.Rosenhas25yearsofexperiencein...ingkeyrolesatGileadSciencesandALZACorporation.Hisa...ardtosix. ,, "Howiebringsawealthofproductdevelo...
(Date:11/20/2009)..., , , , , , , ,...AUDIO: , A team of scientists from Washington...a, Cold Spring Harbor Laboratory and Iowa State Un...The... , , Click here for more in... , , , , , , , ...
Breaking Biology Technology:Sporicidin Brand Disinfectant Kills H1N1 in 3 Minutes 2Inimex Announces Appointment of New CEO 2Pearl Therapeutics Appoints Howie Rosen to Board of Directors 2Amaizing: Corn genome decoded 2Amaizing: Corn genome decoded 3Amaizing: Corn genome decoded 4
...Pharsight,s Diabetes Meta-Database to Quantify Co...-Based Decision-Making,...ation (OTC Bulletin Board: PHST), a leading provid...ng clinical drug development, today,announced that...s,meta-database to a global biotechnology company....
...cals,Inc. (Nasdaq: ANDS ), a biopharmaceutical co...zation of novel medicines for the treatment of,hep...nnounced that Steve,Worland, Ph.D. has been promot...e Officer, replacing Lawrence C. Fritz, Ph.D. who ...as also been appointed as a member of the,Company,...
...ics NV (Euronext,Brussels: THR), a biotechnology c...es a business update and its financial results for...g this period, ThromboGenics has raised,additional...as continued to,make good progress with its clinic...a total of 5,166,517 shares, which increased,the c...
Other Biology Technology:Pharsight Achieves First License Sale for Public-Source Database 2Pharsight Achieves First License Sale for Public-Source Database 3Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer 2Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer 3ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007 2ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007 3ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007 4ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007 5ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007 6ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007 7ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007 8ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007 9ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007 10ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007 11
(Date:11/23/2009)..., DURHAM, N.H. University of New Hampshire mic...aling $498,115 to advance understanding of the act...ential to enrich nutrient-poor and contaminated so...ure (USDA) awarded Tisa, a professor of molecular,...lore the symbiotic relationship between the bacter...
(Date:11/23/2009)..., , , , , , , , , , ... , , AUDIO: , Dr Andrew Mar...ersity of York, discusses the discovery of Kinyon... , Click here for more information... , , , , , , , ...
(Date:11/23/2009)..., Carlos Mara Romeo Casabona is Director of the I... Genome at Deusto University and the University of...made up of jurists but also has other experts such..., medicine and even specialists in ethics. , The...ne Genome at the Universities of Deusto and the Ba...
Breaking Biology News(10 mins):UNH prof. receives nearly $500,000 to research environmentally significant plants 2New chameleon species discovered in East Africa 2New chameleon species discovered in East Africa 3Research and legislation should go hand in hand, as much as possible 2FDA Approves LIVALO 28R 29 for Primary Hypercholesterolemia and Combined Dyslipidemia 53559 1FDA Approves LIVALO 28R 29 for Primary Hypercholesterolemia and Combined Dyslipidemia 53559 2FDA Approves LIVALO 28R 29 for Primary Hypercholesterolemia and Combined Dyslipidemia 53559 3FDA Approves LIVALO 28R 29 for Primary Hypercholesterolemia and Combined Dyslipidemia 53559 4Corrected 3A Secretary of Health Urges Pennsylvanians to Get Immunized 53557 1Corrected 3A Secretary of Health Urges Pennsylvanians to Get Immunized 53557 2Corrected 3A Secretary of Health Urges Pennsylvanians to Get Immunized 53557 3W M Keck Foundation Awards 241 Million to Hutchinson Center Scholar to Study How Cells Go Awry 13337 1W M Keck Foundation Awards 241 Million to Hutchinson Center Scholar to Study How Cells Go Awry 13337 2
... " Vaccine " published a paper by the Massachusett...ing that a protein sequence important in neurodege...s a new generation of vaccine adjuvants. , The m... elicits specific immunity to a particular virus, ...antigens is one of the most pressing medical and p...
...itute of Singapore (GIS), a research institute ,of...logy and Research (A*STAR), and the University of ...acological approach to kill colon cancer cells. ,...of a protein called Wnt/β-catenin, which is o...ignance, play important roles in ,colorectal cance...
...ists were surprised with findings of a recent stud...sist in small contained areas actually need broad,...more species at risk of extinction today than any ...tudy published in the debut issue of Conservation... protection for many species worldwide. Scientist...
Other Biology News:A protein sequence associated with Huntington’s disease may become life-saving vaccine component 2New study reveals large scale conservation essential 2New study reveals large scale conservation essential 3
...rotein is in solution or in a gel piece, we can id...roteins will be digested to produce a mixture of p...des are determined by MALDI-TOF, and the amino aci...LDI-TOF will be determined by MALDI-TOF/TOF. The m...
Factor Xa Protease from QIAGEN
...s for interferons are cytopathic effect inhibition...Sample types include; tissue culture supernatents;... In these assays, one unit is defined as the quant...e the cytopathic effect of viral infection by 50%....
...s for interferons are cytopathic effect inhibition...Sample types include; tissue culture supernatents;... In these assays, one unit is defined as the quant...e the cytopathic effect of viral infection by 50%....
Biology Products: